Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-17-225214
Filing Date
2017-07-10
Accepted
2017-07-10 16:20:06
Documents
12
Period of Report
2017-07-31
Effectiveness Date
2017-07-10

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE SPECIAL PROXY d400617ddef14a.htm DEF 14A 162000
2 GRAPHIC g400617img1.jpg GRAPHIC 32941
3 GRAPHIC g400617img10.jpg GRAPHIC 1180
4 GRAPHIC g400617img11.jpg GRAPHIC 5343
5 GRAPHIC g400617img2.jpg GRAPHIC 2721
6 GRAPHIC g400617img3.jpg GRAPHIC 2973
7 GRAPHIC g400617img4.jpg GRAPHIC 57474
8 GRAPHIC g400617img5.jpg GRAPHIC 2954
9 GRAPHIC g400617img7.jpg GRAPHIC 14302
10 GRAPHIC g400617img8.jpg GRAPHIC 920
11 GRAPHIC g400617img9.jpg GRAPHIC 1175
12 GRAPHIC g400617pcimg6.jpg GRAPHIC 16444
  Complete submission text file 0001193125-17-225214.txt   354572
Mailing Address 2929 SEVENTH STREET SUITE 100 BERKELEY CA 94710
Business Address 2929 SEVENTH STREET SUITE 100 BERKELEY CA 94710 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34207 | Film No.: 17958032
SIC: 2834 Pharmaceutical Preparations